Edward J. Dulac III - 25 Jan 2022 Form 4 Insider Report for FATE THERAPEUTICS INC (FATE)

Role: Chief Financial Officer
Signature: /s/ Cindy Tahl, Attorney-in-Fact
Issuer symbol: FATE
Transactions as of: 25 Jan 2022
Net transactions value: $0
Form type: 4
Filing time: 27 Jan 2022, 15:35:22 UTC
Previous filing: 13 Jan 2022
Next filing: 19 Aug 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	FATE	Common Stock	Award	$0	+33,302	+31%	$0.000000	141,936	25 Jan 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	FATE	Stock Option (Right to Buy)	Award	$0	+53,058		$0.000000	53,058	25 Jan 2022	Common Stock	53,058	$39.87	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Award of restricted stock units that vest with respect to 1/4th of the underlying shares on each of January 8, 2023, January 8, 2024, January 8, 2025 and January 8, 2026, subject to the Reporting Person's continued service with the Issuer as of each such date.
F2	The shares subject to this option vest in 48 equal month installments beginning on February 1, 2022 such that this option will be fully exercisable on January 1, 2026, subject to the Reporting Person's continued service with the Issuer as of each such date.